Apollomics, a late-stage clinical biopharmaceutical company, agreed to go public via a merger with Maxpro Capital Acquisition, a blank check company, in an $899m deal. "Our goal was to find an exciting company with a growing pipeline of innovative product candidates that could positively affect the lives of millions of people. Our team is excited to combine with Apollomics as it has met and exceeded all our key selection criteria. Together with Apollomics, Maxpro will do everything we can to support the Company’s vision of treating patients with difficult-to-treat cancers," Moses Chen, Maxpro CEO.